SiteOne Therapeutics Announces Initiation of Phase 1 Clinical Trial for its Non-Opioid Analgesic for Acute Pain

Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ -- SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company's Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain.
"The initiation of this study represents a significant milestone for the company as it is our first drug candidate to enter the clinic," stated John Mulcahy, Ph.D., chief executive officer of SiteOne
. "There is an urgent, unmet need to develop effective non-opioid therapies for pain. Our lead compound, ST-2427, addresses that need by targeting the peripheral nerve fibers that conduct pain signals without the potential for CNS side effects, addiction and abuse liability of opioid medications."

Related Keywords

Kansas ,United States ,Debra Odink ,David Schull ,John Mulcahy ,National Institute On Drug Abuse ,National Institutes Of Health ,Prnewswire Siteone Therapeutics Inc ,Siteone Therapeutics Inc ,Russo Partners ,Bone Therapeutics ,Overland Park ,National Institute ,Drug Abuse ,National Institutes ,Award Number ,கன்சாஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,ஜான் முல்கேஹீ ,தேசிய நிறுவனம் ஆன் மருந்து ,தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் ,சீட்டேோனே சிகிச்சை இன்க் ,ருஸ்ஸோ கூட்டாளர்கள் ,ஒன்று சிகிச்சை ,ஓவர்‌ல்யாஂட் பூங்கா ,தேசிய நிறுவனம் ,மருந்து ,தேசிய நிறுவனங்கள் ,விருது எண் ,